Similar articles

• Within-patient controlled assessment of the influence of basiliximab on cyclosporine in pediatric de novo renal transplant recipients.

  Kovarik JM, Korn A, Chodoff L. Kovarik JM, et al. Transplant Proc. 2001 Nov-Dec;33(7-8):3172-3. doi: 10.1016/s0041-1345(01)02350-8. Transplant Proc. 2001. PMID: 11750361 Clinical Trial. No abstract available.
• Pharmacokinetics and pharmacodynamics of a chimeric interleukin-2 receptor monoclonal antibody, basiliximab, in renal transplantation: a comparison between Japanese and non-Japanese patients.

  Haba T, Uchida K, Katayama A, Tominaga Y, Sato T, Watanabe I, Inagaki H, Kimata T, Goto K, Morozumi K, Takeda A, Takahara S, Takahashi K, Oshima S. Haba T, et al. Transplant Proc. 2001 Nov-Dec;33(7-8):3174-5. doi: 10.1016/s0041-1345(01)02351-x. Transplant Proc. 2001. PMID: 11750362 No abstract available.
• Basiliximab: a review of its use as induction therapy in renal transplantation.

  McKeage K, McCormack PL. McKeage K, et al. BioDrugs. 2010 Feb 1;24(1):55-76. doi: 10.2165/11203990-000000000-00000. BioDrugs. 2010. PMID: 20055533 Review.
• Efficacy and tolerability of interleukin-2 receptor blockade with basiliximab in pediatric renal transplant recipients.

  Vester U, Kranz B, Testa G, Malagò M, Beelen D, Broelsch CE, Hoyer PF. Vester U, et al. Pediatr Transplant. 2001 Aug;5(4):297-301. doi: 10.1034/j.1399-3046.2001.005004297.x. Pediatr Transplant. 2001. PMID: 11472610
• [Anti IL-2 receptor antibody--basiliximab].

  Nakagawa Y, Saitou K, Takahashi K. Nakagawa Y, et al. Nihon Rinsho. 2005 May;63 Suppl 5:713-7. Nihon Rinsho. 2005. PMID: 15954434 Review. Japanese. No abstract available.